Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
Not yet recruiting · NCT07797036 · Registry updated 2026-09-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus | Female Urogenital Diseases and Pregnancy Complications, Insulin Resistance, Nutritional and Metabolic Diseases, Urogenital Diseases, diabetes mellitus, endocrine system disorder, gestational diabetes, glucose metabolism disease, hyperinsulinism, metabolic disease, pregnancy disorder | Not yet recruiting | Phase 2 / Phase 3 | 2026-09-28 | NCT07797036 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Massachusetts, Worcester | 90 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UMass Memorial | Worcester | United States | 1 |